(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.37%) $82.70
(6.19%) $2.04
(-0.03%) $2 346.50
(-0.23%) $27.47
(3.84%) $957.55
(-0.21%) $0.933
(-0.33%) $10.99
(-0.54%) $0.796
(1.67%) $93.41
-11.91% $ 6.40
@ $9.09
Ausgestellt: 5 Apr 2024 @ 22:00
Rendite: -29.65%
Vorheriges Signal: Apr 4 - 20:18
Vorheriges Signal:
Rendite: -0.66 %
Live Chart Being Loaded With Signals
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis...
Stats | |
---|---|
Tagesvolumen | 4.83M |
Durchschnittsvolumen | 4.65M |
Marktkapitalisierung | 453.38M |
EPS | $0 ( 2024-03-27 ) |
Nächstes Ertragsdatum | ( $-0.360 ) 2024-05-09 |
Last Dividend | $873.01 ( 2017-01-20 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.85 |
ATR14 | $0.0170 (0.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-02 | Roberts M Scot | Buy | 7 775 | Common Stock, par value $0.0001 |
2024-02-02 | Roberts M Scot | Sell | 2 330 | Common Stock, par value $0.0001 |
2024-02-01 | Roberts M Scot | Buy | 6 166 | Common Stock, par value $0.0001 |
2024-02-01 | Roberts M Scot | Sell | 1 801 | Common Stock, par value $0.0001 |
2024-02-02 | Roberts M Scot | Sell | 7 775 | Restricted Stock Units |
INSIDER POWER |
---|
81.81 |
Last 99 transactions |
Buy: 2 849 671 | Sell: 279 919 |
Volumen Korrelation
Altimmune Inc Korrelation
10 Am meisten positiv korreliert | |
---|---|
EBET | 0.973 |
APEI | 0.968 |
STRM | 0.966 |
SY | 0.964 |
ENTA | 0.963 |
IMBI | 0.963 |
CASA | 0.958 |
SISI | 0.958 |
CAMP | 0.957 |
NSTG | 0.957 |
10 Am meisten negativ korreliert | |
---|---|
LDHA | -0.979 |
JUGG | -0.979 |
ADAL | -0.978 |
CRZN | -0.977 |
HORI | -0.976 |
AHRN | -0.974 |
AGGR | -0.974 |
TBSA | -0.974 |
HCNE | -0.973 |
LEGA | -0.973 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Altimmune Inc Korrelation - Währung/Rohstoff
Altimmune Inc Finanzdaten
Annual | 2023 |
Umsatz: | $426 000 |
Bruttogewinn: | $-51 000.00 (-11.97 %) |
EPS: | $-1.660 |
FY | 2023 |
Umsatz: | $426 000 |
Bruttogewinn: | $-51 000.00 (-11.97 %) |
EPS: | $-1.660 |
FY | 2022 |
Umsatz: | $-68 000.00 |
Bruttogewinn: | $-136 000 (200.00 %) |
EPS: | $-1.810 |
FY | 2021 |
Umsatz: | $4 410.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-0.00379 |
Financial Reports:
No articles found.
Altimmune Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $873.01 | 2017-01-20 |
Last Dividend | $873.01 | 2017-01-20 |
Next Dividend | $0 | N/A |
Payout Date | 2017-02-03 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $873.01 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $873.01 | 655.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -203.67 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.412 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.510 | 1.500 | -6.78 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 17.25 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 16.69 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 11.13 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00319 | -1.500 | 9.95 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3 630.87 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.297 | 2.00 | -0.432 | -0.865 | [0 - 30] |
freeCashFlowPerShareTTM | -1.298 | 2.00 | -0.649 | -1.298 | [0 - 20] |
debtEquityRatioTTM | 0.00346 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -76.88 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -196.03 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -112.98 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00202 | 0.800 | -3.32 | -2.66 | [0.5 - 2] |
Total Score | -0.982 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -4.89 | 1.000 | -0.595 | 0 | [1 - 100] |
returnOnEquityTTM | -0.510 | 2.50 | -4.36 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.298 | 2.00 | -0.433 | -1.298 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.297 | 2.00 | -0.432 | -0.865 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0709 | 1.500 | -3.81 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -177.96 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.